RESEARCH ARTICLE

Open Access

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells

Håkon Reikvam 1*, Randi Hovland 2, Rakel Brendsdal Forthun 3, Sigrid Erdal 2, Bjørn Tore Gjertsen 3, Hanne Fredly 3 and Øystein Bruserud 3

Abstract

Background: Acute myeloid leukemia (AML) is an aggressive malignancy only cured by intensive therapy. However, many elderly and unfit patients cannot receive such treatment due to an unacceptable risk of treatment-related morbidity and mortality. Disease-stabilizing therapy is then the only possible strategy, one alternative being treatment based on all-trans retinoic acid (ATRA) combined with the histone deacetylase inhibitor valproic acid and possibly low-toxicity conventional chemotherapy.

Methods: Primary AML cells were derived from 43 patients included in two clinical studies of treatment based on ATRA, valproic acid and theophyllamine; low toxicity chemotherapy (low-dose cytarabine, hydroxyurea, 6-mercaptopurin) was also allowed. Pretreatment leukemic cells were analyzed by mutation profiling of 54 genes frequently mutated in myeloid malignancies and by global gene expression profiling before and during in vivo treatment.

Results: Patients were classified as responders and non-responders to the treatment, however response to treatment showed no significant associations with karyotype or mutational profiles. Significance analysis of microarray (SAM) showed that responders and non-responders significantly differed with regard to the expression of 179 different genes. The differentially expressed genes encoding proteins with a known function were further classified based on the PANTHER (protein annotation through evolutionary relationship) classification system. The identified genes encoded proteins that are involved in several important biological functions, but a main subset of the genes were important for transcriptional regulation. These pretherapy differences in gene expression were largely maintained during treatment. Our analyses of primary AML cells during in vivo treatment suggest that ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3), but altered function of DNA methyl transferase 3A (DNMT3A) and G-protein coupled receptor signaling may also contribute to the effect of the overall treatment.

Conclusions: Responders and non-responders to AML stabilizing treatment based on ATRA and valproic acid differ in the pretreatment transcriptional regulation of their leukemic cells, and these differences may be important for the clinical effect of this treatment.

Trial registrations: ClinicalTrials.gov no. NCT00175812; EudraCT no. 2004–001663-22, registered September 9, 2005 and ClinicalTrials.gov no. NCT00995332; EudraCT no. 2007–2007–001995-36, registered October 14, 2009.

Keywords: Acute myeloid leukemia, All-trans retinoic acid, Valproic acid, Gene expression profiling

* Correspondence: Hakon.Reikvam@med.uib.no; hakon.reikvam@uib.no
1Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Acute myelogenous leukemia (AML) is an aggressive malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. AML are distinguished from other related blood disorders by the presence of >20% blasts in the bone marrow [1]. The only possibility for cure is intensive induction chemotherapy followed by consolidation treatment with intensive chemotherapy or stem cell transplantation, although for various reasons this treatment is not possible for several elderly or unfit patients [2–4]. Firstly, elderly patients have a higher and often unacceptable risk of severe treatment-related complications compared with younger patients [2–4]. The median age at the time of diagnosis of AML is 65–70 years and elderly patients thus represent the largest group of AML patients [1]. Secondly, unfit patients with severe comorbidity also have an unacceptable risk of severe complications and treatment-related mortality. Thirdly, several patients with relapsed or resistant disease will not receive further intensive treatment [5]. All these groups constitute a relatively large patient population that should be considered for AML-stabilizing treatment, e.g. treatment based on all-trans retinoic acid (ATRA) + valproic acid and low-toxicity cytotoxic treatment with hydroxyurea, 6-mercaptopurin or low-dose cytarabine [6–11].

New treatment approaches are currently considered for AML patients unfit for intensive chemotherapy. A promising concept is modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs) [12]. These enzymes alter acetylation of histones as well as transcription factors and other proteins involved in the regulation of cellular proliferation and survival. Valproic acid has features as a HDAC inhibitor, and are currently investigated in clinical studies of elderly or unfit AML patients, often in combination with ATRA [13, 14]. The toxicity of this treatment is low. Complete hematological remission lasting for several months has been reported for a minority (<5–10%) of patients but increased peripheral blood platelet counts are seen for 30–40% of patients and may last for up to 1–2 years [13, 14]. Valproic acid and ATRA may also be combined with conventional low-toxicity chemotherapy [7, 13, 14].

ATRA is a vitamin A metabolite that binds to retinoid-responsive nuclear receptors and thereby exerts effects on cell growth, differentiation and apoptosis [15]. It is used in the treatment of acute promyelocytic leukemia (APL) [16], although may also have antileukemic effects in non-APL variants of AML [17–19]. HDAC-inhibitors can reduce proliferation and induce differentiation in malignant hematopoietic cells [20], and these effects seem to be enhanced in combination with ATRA [21, 22]. The combination of valproic acid, ATRA and possibly low-toxicity chemotherapy has been examined in several clinical studies of AML patients with non-APL disease [14]. In this context we compared genetic abnormalities and gene expression patterns for responders and non-responders patients to low-toxicity treatment based on the combination of ATRA and valproic acid.

Methods

Patient characterization and classification

Patients included

A large group of consecutive AML patients unfit for intensive chemotherapy was included in two different phase 1/2 studies [9, 13]. Both the first study, including 24 patients, and the second study, including 36 patients were approved, by the Regional Ethics committee (REK Vest 215.03 and 231.06, respectively) and registered in a public database (for the first study ClinicalTrials.gov number NCT00175812 and EudraCT number 2004–001663-22; for the second study ClinicalTrials.gov number NCT00995332 and EudraCT number 2007–2007–001995-36 respectively). All patients were included after written informed consent.

A total of 60 patients unfit for more intensive therapy were included in the two studies; their characteristics are summarized in Additional file 1: Table S1. A majority of them were elderly patients with high-risk disease (i.e. leukemia relapse, secondary AML or high-risk cytogenetic abnormalities). Detailed information of all patients included in our present study are given in Additional file 1: Table S2.

During the time periods for the two clinical studies 9 additional patients unfit for intensive treatment were also diagnosed at our department; these patients were not included in the clinical studies because they (i) did not accept inclusion (1 patient); (ii) informed consent (6 patients) or (iii) adequate follow-up was not possible (1 patient); and (iv) hydroxyurea treatment was already started (1 patient).

The antileukemic treatments in the two clinical studies are summarized in Additional file 1: Table S3. Both protocols were based on intermittent ATRA therapy for 2 weeks at 12 weeks intervals, continuous oral valproic acid treatment and additional low-dose chemotherapy given either as (i) hydroxyurea (daily)/6-mercaptopurine (daily)/low-dose cytarabine (at least 4 weeks intervals) to maintain peripheral blood blast counts below 50 × 10⁹/L (the 24 patient in study 1) [9]; or (ii) low-dose cytarabine at 12 weeks intervals as long as peripheral blood blast counts were below 50 × 10⁹/L, this being replaced by oral hydroxyurea/6-mercaptopurine if blast counts increased (the 36 patients in study 2) [13]. A total of 28 patients were included in the global gene expression studies of pretreatment primary AML cells (see Table 1; 17 from the first and 11 from the second study; 14 males and 14 females; median age 76 years with range 48–87 years).
Table 1: Comparison of global gene expression profiles for responders and non-responders to AML stabilizing treatment based on ATRA and valproic acid – a summary of the results from the Gene Set Enrichment Analysis (GSEA)

| GENE SET                                      | SIZE | ES   | NES | NOM  | P-VALUE |
|----------------------------------------------|------|------|-----|------|---------|
| Signal sequence binding                      | 21   | −0.62| −1.85| <0.01|         |
| Olfactory bulb interneuron development       | 10   | −0.72| −1.77| <0.01|         |
| Negative regulation of MAPK cascade          | 38   | −0.5 | −1.76| <0.01|         |
| Response to ionizing radiation               | 85   | −0.45| −1.69| <0.01|         |
| Zinc ion transport                           | 16   | −0.67| −1.76| 0.01  |         |
| Pre-mRNA binding                             | 13   | −0.7 | −1.73| 0.01  |         |
| Positive regulation of oxidoreductase activity | 14   | −0.65| −1.73| 0.01  |         |
| Inactivation of MAPK activity                | 27   | −0.48| −1.62| 0.01  |         |
| Regulation of interferon-gamma biosynthetic process | 16   | −0.6 | −1.61| 0.01  |         |
| Carboxylic acid catabolic process            | 34   | −0.45| −1.61| 0.01  |         |
| Response to radiation                        | 189  | −0.37| −1.56| 0.01  |         |
| Negative regulation of reactive oxygen species metabolic process | 11   | −0.64| −1.68| 0.02  |         |
| Regulation of bone resorption               | 10   | −0.7 | −1.66| 0.02  |         |
| RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription | 11   | −0.62| −1.65| 0.02  |         |
| Biotin metabolic process                     | 10   | −0.73| −1.65| 0.02  |         |
| Regulation of isotype switching             | 20   | −0.55| −1.64| 0.02  |         |
| Fucosyltransferase activity                 | 14   | −0.64| −1.65| 0.03  |         |
| Microtubule bundle formation                | 24   | −0.52| −1.6  | 0.03  |         |
| Negative regulation of JNK cascade           | 22   | −0.59| −1.59| 0.03  |         |
| UV protection                               | 11   | −0.6 | −1.56| 0.03  |         |
| MutSalpha complex binding                   | 11   | −0.72| −1.59| 0.04  |         |
| Aminopeptidase activity                     | 34   | −0.47| −1.58| 0.04  |         |
| Mismatch repair complex                     | 10   | −0.74| −1.57| 0.04  |         |
| Negative regulation of transcription by competitive promoter binding | 10   | −0.61| −1.56| 0.04  |         |
| Cholesterol efflux                          | 25   | −0.51| −1.55| 0.04  |         |
| Negative regulation of cytoskeleton organization | 51   | −0.41| −1.51| 0.04  |         |
| Regulation of protein localization to cell surface | 17   | −0.53| −1.51| 0.04  |         |
| Response to gamma radiation                 | 32   | −0.44| −1.47| 0.04  |         |

Abbreviations: ES enrichment score, JNK c-Jun N-terminal kinases, MAPK mitogen-activated protein kinase, NES normalized enrichment score

Only 16 of the 28 patients had de novo AML, the others had either AML secondary to chronic myeloproliferative neoplasmia (3 patients), previous chemotherapy (1 patient) or myelodysplastic syndrome (MDS, 5 patients); 3 additional patients had AML relapse. Seventeen patients had normal karyotype and 7 had adverse karyotype; 10 patients had FLT3-ITD. Twenty-three patients could be classified as having unfavorable prognosis having at least one of the following criteria: High-risk karyotype (7 patients), AML relapse (3 patients) or secondary AML (9 patients).

**Treatment**

Patients included in the Study 1 were treated with oral ATRA 22.5 mg/m² twice daily days 1–14, and valproic acid together with theophyllamine from day 3 until disease progression [9]. The treatment with valproic acid and theophyllamine started with an initial intravenous loading dose followed by 48 h of intravenous infusion guided by the serum levels before the oral treatment. For valproic acid the loading dose of 5 mg/kg was administered during 30 min and continued as an intravenous infusion of 28 mg/kg/24 h. For theophyllamine the loading dose of 5 mg/kg was administered over 30 min and continued as an intravenous infusion of 0.65 mg/kg/h. Samples were collected before treatment (day 1), after 2 days of treatment with ATRA alone (day 3) and after 5 additional days of treatment with the triple combination (day 8). ATRA was repeated with 12 weeks intervals (Study registration: ClinicalTrials.gov no. NCT00175812 and EudraCT no.2004–001663-22).

Patients included in study 2 were treated with valproic acid from day 1 and until disease progression, oral ATRA 22.5 mg/m² twice daily days 8–22 and subcutaneous cytarabine 10 mg/m² administered once daily on days 15–24 [13]. The treatment with ATRA/cytarabine was repeated with 12 weeks intervals. Treatment with valproic acid started with an intravenous loading dose and thereafter an intravenous infusion for 24 h before the treatment was continued as oral administration guided by the serum level. Samples were collected before treatment (day 1) (Study registration: ClinicalTrials.gov no. NCT00995332 and EudraCT no. 2007–001995-36).

**Response criteria**

The international working group in AML [23, 24] defined complete remission (CR) of AML as (i) less than 5% blast in the bone marrow, no Auer rods and no persistence of extra-medullary disease, and (ii) neutrophil counts above $1.0 \times 10^9$/L, platelet levels above $100 \times 10^9$/L and erythrocyte transfusion independence. There is no requirement in terms of duration of this response. The MDS response criteria [24, 25] generally require a duration of 8 weeks for the response. The requirements for CR in MDS are (i) less than 5% blasts in the bone marrow and no dysplasia, (ii) hemoglobin level $>11$ g/100 ml, neutrophils counts $>1.5 \times 10^9$/L, platelets counts $>100 \times 10^9$/L and (iii) no circulating blasts. The MDS criteria also define stable disease as no evidence of progression for at least 8 weeks. Patients referred to as responders in
our present study corresponded to patients achieving either (i) complete remission as defined by the AML criteria lasting for at least 8 weeks or (ii) fulfilling the MDS criteria for at least stable disease or hematological improvement with increased normal peripheral blood cell counts.

Cell preparation
The 28 patients included in the microarray studies represent the subset of patients with high enough peripheral blood blast counts to allow sampling from the peripheral blood of sufficient cells for microarray studies. Leukemic peripheral blood mononuclear cells (PBMCs) were isolated by density gradient separation (Ficoll-Hypaque; NycoMed, Oslo, Norway; specific density 1.077) from peripheral blood of patients with at least 80% of the leukocytes being AML cells. Cells were stored frozen in liquid nitrogen. The percentage of AML blasts among leukemia PBMC exceeded 95% [26].

Mutation profiling
Submicroscopic mutation profiling of 54 genes frequently mutated in myeloid leukemias was done by the Illumina’s TruSight Myeloid Gene Panel and sequenced using the MiSeq system and reagent kit v3 (all from Illumina, San Diego, CA, USA) (Additional file 1: Table S4). Amplicon sequencing library was prepared from 50 ng DNA according to the manufacturer’s instructions with the exception of normalizing being done manually. 8–16 samples were sequenced each time and the total DNA input on the flow cell was 15 picomolar. Secondary analysis was performed using MiSeqReporter version 2.4.60.8 (Illumina) mapping to the human genome reference hg19. Sequence alignment of selected variants was manually examined with the Integrative Genomics Viewer (IGV) [27]. Annotation was done by snpSIFT og snpEFF v 4.1. As no matching normal DNA was available variants with >1% minor allele frequency in the 1000 genomes data were presumed to be germline and removed from further interpretations. Synonymous substitutions, intronic variants not in the splice site and variant interpreted as benign or most likely benign are not included. The variant allele frequency (VAF) was calculated for each mutation as number of variant reads divided by total reads. Cut-off for reported variants for VAF was 8% and read depth 100. Only variants interpreted as pathogenic, probably pathogenic and variants of unknown significance are reported. The nomenclature is according to Human Genome Structural Variation consortium.

Fragment analysis of FLT3 exon 14–15 and NPM1 exon 12 were done as described in [28] and CEBPA mutation analysis as described previously [28].

RNA preparation, labelling and microarray hybridization
All microarray experiments were performed using the Illumina iScan Reader, which is based upon fluorescence detection of biotin-labelled cRNA. Three hundred ng of total RNA from each sample was reversely transcribed, amplified and Biotin-16-UTP-labelled using the Illumina TotalPrep RNA Amplification Kit (Applied Biosystems/Ambion, USA). The amount and quality of the Biotin-labelled cRNA (750 ng) was hybridized to the HumanHT-12 V4 Expression BeadChip according to the manufacturer’s instructions. The HumanHT-12 V4 BeadChip targets 47,231 probes that are mainly derived from genes in the NCBI RefSeq database (Release 38).

Preprocessing, normalization and annotations of microarray data
Data from the array scanning were investigated in GeneStudio and J-Express 2012 for quality control measures [29]. All arrays within each experiment were quantile normalized to be comparable before being compiled into an expression profile data matrix. The probe with the highest fluorescence was used in the analyses if the expression of the same gene was examined by different probes. In all our analyses of gene expression profiles we used significant analyses of microarray (SAM) [30], and gene set enrichment analysis (GSEA) [31], to compare different patient subsets or samples. The genes encoding proteins with a known function were classified by using the PANTHER (protein annotation through evolutionary relationship) classification system [32].

Results
Classification of patients as responders and non-responders to ATRA/valproic acid
All patients in the present study were included in two previous clinical studies. These studies included 60 patients (20 responders); the characteristics of all patients are summarized in Additional file 1: Table S1 and the characteristics of individual patients included in the present study are presented in Additional file 1: Table S2. Additional analysis of the mutational profiles was possible for 12 responders and 29 non-responders to the treatment (Additional file 1: Table S3; patients 1–12 and 15–43). The effects of antileukemic treatment on gene expression profile were analyzed for eight patients from the study by Ryningen et al. [13]. A high frequency of patients with high-risk disease according to conventional prognostic criteria (i.e. AML relapse, secondary AML, high-risk cytogenetic abnormalities) was seen both for the whole group of 60 patients, the 41 patients included in the study of mutational profiles (Additional file 1: Table S2;
patients 7, 8, 17, 23, 26, 31, 38 and 42). None of the patients had low-risk cytogenetic abnormalities.

**Responsiveness to AML-stabilizing therapy was not significantly associated with karyotype or the mutational profile**

A detailed submicroscopic mutational profile was examined for 41 patients (Additional file 1: Table S2; 12 responders and 29 non-responders); the profile included genes frequently mutated in myeloid malignancies (Additional file 1: Table S4, Fig. 1). Thirty-two of these genes were mutated in at least one of the patients, and according to previous studies [33, 34] these mutations were classified as (i) NPM1 mutations, (ii) mutations causing activation of intracellular signaling; (iii) mutated tumor suppressor genes; (iv) mutations in genes involved in DNA methylation or (v) chromatin modification; (vi) mutations in genes encoding myeloid transcription factors; (vii) mutated genes important for the spliceosome or (viii) encoding cohesion protein; and (ix) others.

The number of detected mutations differed between patients, the median number being three mutations (range 0–7). Responders and non-responders did not differ with regard to the number of mutations. FLT3 mutations were most frequent (15 out of 41 patients, 37%) followed by NPM1 mutations (14/41, 34%). Most patients had at least one mutation causing activation of intracellular signaling (25/41, 61%), and all six patients with TP53 mutations had an adverse karyotype. Even though NPM1, FLT3, TP53 and DNMT3A mutations showed higher frequencies for non-responders than for responders, these differences did not reach statistical significance.

The gene expression profiles of responders and non-responders to AML-stabilizing treatment differ especially for genes important in nucleic acid binding, intracellular transport, function of hydrolases and modulation of enzyme activity

We compared the global gene expression profiles for pretreatment AML cell samples derived from 28 patients who later could be classified as responders or non-responders to the leukemia-stabilizing treatment. All these AML cell samples were derived from patients with

![Fig. 1 Mutational profiling of responders and non-responders to AML-stabilizing treatment based on ATRA plus valproic acid. Primary AML cells derived from 41 patients (Additional file 1: Table S2; patients 1–2 and 15–43) were analyzed for AML-associated mutations (see Additional file 1: Table S4). The 41 patients included 12 responders and 29 non-responders to the treatment. The patient numbers at the top of the figure refer to the numbers given in Additional file 1: Table S2, and the figure presents the results only for those mutations that were detected for at least one of these patients. The classification of the mutations can be seen in the left part of the figure. The karyotype classification is given at the bottom of the figure, whereas more detailed information about the cytogenetic abnormalities are included in Additional file 1: Table S2.](image-url)
high peripheral blood blast counts, and highly enriched AML cell populations could thereby be prepared by a simple and highly standardized method based on gradient separation. Nineteen of these patients were classified as non-responders and nine as responders according to the criteria previously described in detail by Fredly et al. [13]. We used SAM to compare the global gene expression profiles for responders and non-responders. When setting the d-score to ±2.5 we identified 243 probes that differed significantly between the two groups, and these probes represent 179 different genes (Additional file 1: Table S5). We then used the Panther database to classify the encoded proteins (Fig. 2), and 159 of these genes encoded proteins that could be classified. Genes encoding for proteins that belonged to the “nucleic acid binding” class were overrepresented (38 out of 159 genes), and these genes encoded both DNA binding protein (16 proteins), RNA binding proteins (20 proteins) and nucleases (2 proteins).

All the genes showing at least a 2-fold difference between responders and non-responders are listed in Additional file 1: Table S6. The proteins encoded by these genes included oncogenes (RGL4, LMO4) as well as regulators of protein degradation/activation/modulation (QPCT, ELANE), transcription (HOXA3, HOXA5, PBX3; the only three with decreased expression), iron metabolism (HP, LT), energy metabolism (MOSC1, CYP4F3, OLR1, SNCA), apoptosis/proliferation (OLFM4, PGLYRP1) and communication (COL17A1, TACSTD2). The Hox genes may be of particular importance, and HOXA4 expression was also significantly lower although the difference was less than two-fold.

We also performed a GSEA. This alternative analysis also showed that the differentially expressed genes are important for a wide range of cellular function, but several of the identified GO-terms with p-value <0.05 describe binding/function/regulation of nucleic acids and showed increased expression for the responders (Table 1).

The effect of in vivo ATRA therapy on the global gene expression profile of primary human AML cells

Transcriptomic profiling of primary AML cells during in vivo ATRA treatment was only possible for eight patients included in the first study [9]. We first compared AML cell samples derived (i) before start of treatment on day 1, and (ii) after two days of oral ATRA monotherapy (day 3). These eight patients were two responders and six non-responders, and due to this low number of available patients it was not possible to compare the effects of ATRA in responders and non-responders. Thus, by this comparison we identified alterations in global gene expression profiles that are common for responders and non-responders. By this approach we could not identify quantitative differences in the expression of these identified genes and probably not effects of ATRA that are specific for responders/non-responders either. However, differences

![Fig. 2](image-url)
between responders and non-responders to ATRA may be caused by different downstream responses to common ATRA-induced alterations, and only such mechanisms are likely to be identified by our strategy for analysis.

We performed a SAM analysis that identified the top ranked differently expressed genes with d-score of ±2.0 (400 permutations) when comparing AML cells sampled on day 1 before ATRA treatment and after two days of treatment on day 3. All differentially expressed genes are listed in Additional file 1: Table S5. The Panther classification analysis based on the function of the encoded proteins (Fig. 3); for these analyses we only included the 70 genes (36 upregulated and 34 downregulated on day 3) that were annotated; these genes can be identified from Additional file 1: Table S5. ATRA altered the expression of genes with a wide range of functions, but a major effect of this in vivo therapy was altered expression of genes encoding proteins that show nucleic acid binding and/or being involved in transcriptional regulation. Additional effects were altered expression of receptor-associated genes, whereas the pretreatment differences between responders and non-responders with regard to hydrolases and enzyme modulation (see above) seem to be maintained during ATRA. However, relatively few genes were altered during ATRA therapy for the 5 terms Nucleic acid binding/transcription factors/enzyme modulation/hydrolases/receptors (see Tables 2 and 3), but the genes encode proteins which are involved both in regulation of DNMT3A (SALL3) and retinol metabolism (RBP1). Finally, there was only a small overlap between those genes showing differential expression when comparing responders and non-responders and those genes being altered by ATRA (Tables 2 and 3). This last observation suggests that the pretreatment differences between responders and non-responders with regard to these 5 terms are maintained during treatment.

The effect of in vivo treatment with valproic acid plus theophyllamine on the global gene expression profile of primary human AML cells

We compared the gene expression profiles for AML cells derived from the same 8 patients before addition of valproic acid and theophyllamine and the ATRA therapy (days 3) and during treatment with the triple combination (day 8). We then did a SAM analyses identifying the top ranked differently expressed genes with d-score of ±2.0 (400 permutations), and thereafter we did a Panther protein classification only based on the 76 annotated genes (39 upregulated and 37 downregulated in day 8 samples). The genes included in the terms transcriptional regulation/nucleic acid binding represent only a minority among the genes with altered expression during the triple drug therapy, and the same was true for the term hydrolases (Figure 3, Table 3, Additional file 1: Table S7). Thus, a major part of the pre-therapy differences between responders and non-responders seem to be maintained during the triple treatment and this was also seen for the separate analyses of ATRA and valproic acid/theophyllamine treatment (see above). The triple therapy altered the expression of genes included in several annotations, but major effects seem to be altered receptor expression/function (especially G-protein coupled receptors for neuromediators, i.e. AVPR1B, GALR2, HCRTR1, GPR151) together with altered expression of transcriptional regulators (Additional file 1: Table S7). Finally, altered expression after valproic acid/theophyllamine was observed for relatively few genes (Table 2) and very few of these genes differed significantly when comparing pre-treatment levels for responders and non-responders (Additional file 1: Table S5), i.e. pre-treatment differences are maintained during treatment.

The overall effect of in vivo treatment with ATRA, valproic acid and theophyllamine on the global gene expression profile of primary human AML cells

We finally compared the effects of the triple drug combination by comparing the global gene expression profiles for primary AML cells derived from the 8 patients before start of treatment and after triple therapy on day 8. The therapeutic serum level for theophyllamine was 55–110 μmol/L. The daily valproic acid dose was increased to the maximal tolerated dose. The therapeutic serum level of valproic acid was 300–600 μmol/L, but the mean valproic acid level during the 5 days of triple treatment varied for individual patients between 178 and 717 μmol/L (median value 407 μmol/L) and did not reach the lower therapeutic limit for 2 of the patients.

We did a SAM analysis identifying the top ranked differentially expressed genes with d-score of ±2.0 (400 permutations), and thereafter we did a Panther protein classification only based on the 76 annotated genes (39 upregulated and 37 downregulated in day 8 samples). The genes included in the terms transcriptional regulation/nucleic acid binding represent only a minority among the genes with altered expression during the triple drug therapy, and the same was true for the term hydrolases (Figure 3, Table 3, Additional file 1: Table S7). Thus, a major part of the pre-therapy differences between responders and non-responders seem to be maintained during the triple treatment and this was also seen for the separate analyses of ATRA and valproic acid/theophyllamine treatment (see above). The triple therapy altered the expression of genes included in several annotations, but major effects seem to be altered receptor expression/function (especially G-protein coupled receptors for neuromediators, i.e. AVPR1B, GALR2, HCRTR1, GPR151) together with altered expression of transcriptional regulators (Additional file 1: Table S7). Finally, altered expression after valproic acid/theophyllamine was observed for relatively few genes (Table 2) and very few of these genes differed significantly when comparing pre-treatment levels for responders and non-responders (Additional file 1: Table S5), i.e. pre-treatment differences are maintained during treatment.
Fig. 3 (See legend on next page.)
Discussion

Most AML patients are elderly and many of these elderly patients as well as younger unfit patients will not benefit from intensive chemotherapy because remission induction is less likely [3, 4] and/or (ii) they have a high risk of severe treatment-related complications and early death due to age, comorbidity or poor performance status [14, 17, 35]. Treatment based on ATRA plus the HDAC inhibitor valproic acid may be an alternative for such patients. However, the in vivo effects of this treatment on the leukemic cells are largely unknown [36, 37].

The treatment of elderly and unfit AML patients often needs to be individualized, and this was also true for the patients included in our present study [9, 13]. Even though our patients were treated according to two different protocols, they all received similar AML-stabilizing treatment (Additional file 1: Table S3) based on ATRA, valproic acid and low-toxicity chemotherapy. Patients with high peripheral blood blast counts at the time of diagnosis received chemotherapy from the start of treatment, otherwise patients in the second protocol received chemotherapy from day 14 and patients in the first protocol received chemotherapy if the peripheral blood blast count increased during treatment. Finally, patients in the first study received theophyllamine, but this was probably less important with regard to clinical efficiency because the frequency of responders in this study was similar to other previous studies of ATRA + valproic acid alone [14].

ATRA was given at the same daily dose as used in APL therapy and in previous studies of non-APL variants of AML treated with ATRA + valproic acid [9, 14, 17]. The tolerated dose of valproic acid varied between patients [9, 13], but previous studies have demonstrated that

---

![Fig. 3](image-url)

Comparison of the global gene expression profiles – a comparison of primary AML cells sampled before treatment (day 1), after treatment with ATRA alone (day 3) and after triple therapy with ATRA, valproic acid and theophyllamine (day 8). Each part of the figure shows the results for one analysis. The upper part presents the comparison of pretreatment samples and cells collected after 2 days of ATRA therapy (day 3 versus pretreatment samples), the middle figure show the effect of adding valproic acid plus theophyllamine to the ATRA therapy (day 8 versus day 3 samples) and the lower figure shows the effect of the triple combination (pretreatment samples versus AML cells sampled on day 8). The same strategies were used for all three analyses. Differentially expressed genes were first identified by SAM, and the functional analyses of the encoded proteins were based on the Panther database. Only genes encoding annotated proteins were included in these analyses. The figures thus present the representative distribution of the genes with known functions that showed differential expression according to the Panther protein class (PS) category. The name of each of the identified classes is given in the figure along with number of genes in each category. Only classes containing ≥ 2 genes are named. The genes included in each of the five major classes nucleic acid binding, transcription factor, enzyme modulator, hydrolase and receptor are listed in Table 2, and important biological functions of individual genes are described in Additional file 1: Table S5.

---

**Table 2**

| Nucleic acid binding/Protein synthesis regulator | Hydrolases | Enzyme modulation | Receptors |
|-----------------------------------------------|------------|------------------|-----------|
| Increased* | Decreased | Increased | Decreased | Increased | Decreased | Increased | Decreased |
| AGAP3 | AARS1D1 | MBTD1 | ACP22 | APOBEC3H | AGAP3 | ARL16 | OLFM4* | ADRA2C |
| ARAP3 | APOBEC3H | MCART1 | AFMID | ATP2A2 | ARAP3 | BRC3 | ST7 | HP* |
| LMO4 | ARAP3 | MRPS15 | LTF* | CDC14A | FBXO8 | GNB4 | TACSTD2* | MCHR2 |
| NLRX1 | DDX5 | MYCBP2 | RNASE4 | ELANE | MCF2L2 | HP* | QRFPR |
| PCBP2 | CDKN2AIP | PBX3 | GNB4 | PCBP2 | MCBP2 | THADA |
| RBM5 | DDX5 | PH4X | HP* | PI3 | MYO3B | XPO1 |
| RNASE4 | FOXP1 | SMC4 | LRAP | RGL4* | PXYB |
| RPL30 | HIST2H2AC | SNRP70 | SMC4 | RNASE4 |
| SNRPB | HOXA3* | TDRD1 | TDP1 | TP53BP2 |
| TAF8 | HOXA4 | THOC | XRCC2 |
| UBL4A | HOXA5* | XRCC2 |
| WRN | LCOR | ZMAT3 |
| LRRF1P1 | ZNF394 |
| MBD2 |

The classification of the genes refer to increased/decreased levels in responders compared with non-responders. Only those genes/probes with an annotation included in the Panther analysis (and thereby also in this table) that is the basis for this classification

Increased or decreased levels means increased expression in responder patients

*Genes with significantly different expression also when comparing responders versus non-responders (see Additional file 1: Table S5)
Table 3 An overview of individual genes that belong to the 5 the GO-terms Nucleic acid binding/transcription factor/hydrolases/enzyme modulation/receptors and their expression in primary human AML cells – effects of in vivo treatment with the triple combination on the gene expression profile

| Comparison (Number of genes included in the comparison) | Nucleic acid binding transcription factor | Hydrolases | Enzyme Modulation | Receptors |
|--------------------------------------------------------|-----------------------------------------|------------|-------------------|-----------|
| Day 1 versus day 3<sup>a</sup>                         | Increased: FOXB1, JRKL                  | Decreased: SALL3 | Increased: ETHE1 | Increased: RBP1, KIAA244 |
|                                                        |                                         |             |                   |           |
| Day 3 versus day 8<sup>b</sup>                         | Increased: RSPH9, SIRT6, ONECUT         | Decreased: SIRT6, KLK1 | Increased: ITH4, ANGBL3, KLK1, GNG12 | Increased: AVPR1B, HS.344170, KLK1, AVPR1B, GALR2 |
|                                                        |                                         |             |                   |           |
| Day 1 versus day 8<sup>c</sup>                         | Increased: NR2F1, PRDM13, ZBTB7C        |             |                   | Increased: CCNE2, SIPA1L1, DYNNL2, ITIH3, MRGPRX4, GPR151 |

These five terms included a major part of the genes that showed differential expression when comparing responders and non-responders. Only genes with known annotations were included in the Panther analysis (and thereby in this table) that forms the basis for the table. The table presents those genes belonging to these five terms altered during treatment. The terms increased/decreased expression means that the indicated genes showed increased/decreased expression during the investigated therapeutic intervention, i.e. during ATRA treatment day 3, following addition of valproic acid plus theophyllamine day 8 and following triple therapy day 8

<sup>a</sup>Increased or decreased on day 3 after ATRA therapy

<sup>b</sup>Increased or decreased on day 8 after addition of valproic acid plus theophyllamine

<sup>c</sup>Increased or decreased on day 8 after triple therapy

clinically relevant effects with improvement of platelet counts can be observed even for patients having concentrations below the therapeutic serum level [14]. Our patients should be regarded as representative for elderly/unfit patients with regard to systemic valproic acid levels [9, 14, 17]. The responses to ATRA + valproic acid based treatment are usually detected after 2–3 weeks [13, 14]. On the other hand, many patients (especially elderly patients) have a short expected survival [13, 14], and if they do not respond to the first AML-stabilizing treatment there may not be sufficient time left to try an alternative treatment. Our present results suggest that gene expression profiling can be used for early identification of patients who are likely to respond to treatment based on ATRA + valproic acid, whereas conventional prognostic criteria (relapse versus first diagnosis, karyotype, molecular genetics) could not be used for prediction of treatment responses.

Several randomized studies have failed to show an effect of ATRA on survival for AML patients receiving intensive and potentially curative chemotherapy (for detailed information and additional references see [38, 39], although a recent study suggests that ATRA improves survival for the subset of patients having NPM1 mutations or having genetic low risk disease [38]. Thus, the effect of ATRA may be observed only for a subset of patients identified by their genetic abnormalities. For this reason we compared the frequencies of various genetic abnormalities for responders and non-responders to our AML-stabilizing treatment, but we could not detect any significant differences between the two groups. This was also true for DNMT3, even though the effect of its regulator SALL3 (see Additional file 1: Table S7) is altered by ATRA. However, these observations have to be interpreted with great care because we investigated only a limited number of molecular abnormalities and compared relatively small groups of patients. Furthermore, our observation that the responders included several patients with high-risk disease according to conventional prognostic criteria also support the conclusion that conventional prognostic parameters (including cytogenetic and molecular-genetic analysis) have a limited value with regard to predicting responsiveness to AML-stabilizing treatment based on ATRA and valproic acid.

Several studies have described effects of ATRA and valproic acid on gene expression in human AML cells [40–44], and we investigated whether the treatment-induced differences in gene expression or differences between our responders and non-responders included genes that had also been identified in these studies (Additional file 1: Table S5). We first compared our results with 241 genes regulated by retinoic acid [40], but only a minority of these genes were altered by ATRA/valproic acid/theophyllamine (NR2F1, PCDH12, SFTPA1B, RBP1) or differed significantly between responders and non-responders (ABCB1, BIRC3, OLR1). Secondly, Zheng et al. [41] identified 108 ATRA responsive genes in the NB4 AML cell line, but only CGREF1 was altered during treatment and only NCOA3 differed significantly between responders and non-responders. Similarly, Park et al. [42] identified 15 genes altered by in vitro exposure of primary AML cells to ATRA; none of them differed between our responders and non-
responders or were altered during treatment. Finally, Bullinger et al. [43] analyzed effects of ATRA on the HL60 AML cell line and detected 427 ATRA-responsive genes; none of their 39 genes with FDR < 0.05 were altered during treatment and only two of these genes (ARAP3, HOX43) differed between our responders and non-responders. However, the decreased levels of HOXA3, HOXA4 and HOX5 together with their modulator PBX3 suggest that HOX genes are important for the response to treatment.

Rücker et al. investigated the in vivo effect of valproic acid for AML patients receiving intensive induction treatment [44]. Neither the expression of their 50 top-ranked genes, the 20 genes in their valproic acid-associated miRNA profile nor their 9 response-predicting genes were altered during treatment of our patients or showed differential expression in responders/non-responders.

Expression a stem cell-like mRNA signature seems to be associated with an adverse prognosis in AML; this has been shown both for a leukemic stem cell related profile (34 genes), hematopoietic stem cell related profile (32 genes) and recently by using a 17-gene stemness scoring system [45, 46]. However, only two of these genes (ABCB1 and HOX5) differed between responders and non-responders, and none of the genes were altered during treatment (Additional file 1: Table S4).

Thus, our present results confirm that both ATRA and valproic acid can alter the expression of a large number of genes involved in a wide range of important cellular processes in primary human AML cells, but only a small number of genes previously shown to be responsive to ATRA or valproic acid were associated with response to treatment or were altered during in vivo treatment of our patients. This lack of overlap suggests that the effects of ATRA/valproic acid on gene expression in human AML cells depend on the biological context during drug exposure.

Recent studies have demonstrated that the mRNA expression of the oncogene EVII, that is important in myeloid malignancies, is induced by ATRA and act as a modulator of ATRA responses [47–49].

Furthermore a substantial part of AML patients with enhanced expression of EVII seem to respond to ATRA by induction of differentiation and decreased clonogenic capacity of myeloid blasts [50]. However, EVII was not associated with ATRA responsiveness and was not induced during ATRA treatment in our patients. These observations are also consistent with the observation that the effects of ATRA depends on the biological context; the EVII observations described above were based on in vitro studies of various cells lines and these effects of EVII/ATRA may then be different from primary AML cells exposed to ATRA in vivo.

Only eight patients were available for global gene expression analyses during in vivo treatment. When analyzing pre-therapy samples in responders and non-responders we conclude that these two groups differ mainly in their expression of genes included in the terms nucleic acid binding, transcription factors, hydrolase and enzyme modulators. These pre-therapy differences were maintained during the triple treatment both when comparing pre-therapy expression with the expression after ATRA alone (day 3 samples) and triple therapy (day 8 samples). The most important differences observed on day 8 compared with pre-therapy samples was altered expression by several receptors. Thus, the final effect of the triple in vivo treatment is maintenance of pretreatment differences between responders and non-responders and the most striking treatment-induced difference being increased expression of several receptors.

Several receptors were upregulated during treatment, and many of them were G-protein coupled receptors and/or receptors for neuromediators. The functions of these receptors in leukemogenesis are largely unknown, although a previous study also suggested that they are expressed by malignant hematopoietic cells and are then involved in growth regulation [51]. Thus, the altered expression of these receptors may thus contribute to the final effect of our AML-stabilizing treatment.

Conclusions

A subset of AML patients responds to disease-stabilizing therapy based on ATRA + valproic acid; the responders include several patients with relapsed/chemoresistant disease and patients with high-risk disease based on their genetic abnormalities. We could not detect any significant differences between responders and non-responders when comparing the frequencies of their genetic abnormalities. Responders and non-responders could be identified by differences in their global gene expression profiles, especially differences in the expression of genes encoding proteins that are important for transcriptional regulation. These differences are maintained during treatment; the triple therapy has only minor effects on the expression of transcriptional regulators but they altered the expression of several receptors.

Additional file 1

Additional file 1: Table S1. The characteristics of the 60 patients included in the two clinical studies. Table S2. Clinical and biological characteristics of the patients included in the study. Table S3. AML-stabilizing treatment based on ATRA plus valproic acid; a summary and comparison of the two treatment regimens. Table S4. Analysis of 54 submicroscopic mutations in primary human AML cells. Table S5. Differences in global gene expression profiles by primary human AML cells derived from responders and non-responders to AML-stabilizing treatment. Table S6. Differences in global gene expression profiles by primary human AML cells derived during AML-stabilizing treatment. Table S7. Differentially expressed genes identified from comparison of primary AML cells before and after treatment. (DOCX 55 kb)
Abbreviations
AML: Acute myelogenous leukemia; APL: Acute promyelocytic leukemia; ATRA: All-trans retinoic acid; CR: Complete remission; GO: Gene-ontology; GSEA: Gene set enrichment analysis; HDAC: Histone deacetylase; MDS: Myelodysplastic syndrome; PBMC: Peripheral blood mononuclear cells; SAM: Significant analyses of microarray; TGFB: Transforming growth factor beta; VAF: Variant allele frequency.

Acknowledgements
The technical assistance of support from Karen Marie Hagen, Kristin Paulsen, Rye, Atle Brendehaug, Hans Petter Brodal, Stian Knappskog and Laura Minsaas are greatly appreciated.

Availability of data materials
Microarray data are available data at Gene Expression Omnibus.

Funding
The study was supported by the Norwegian Cancer Society and Helse-Vest.

Authors’ contributions
HR collected the data, performed the analyses and prepared the figures; RH, RBF and SE performed the genetic analyses; BTG and ØB initiated both clinical studies, ØB was responsible for the first clinical study and for collection of all samples in both studies, HF and ØB were responsible for the second clinical study, HR and ØB designed and coordinated the present study and wrote the manuscript. We confirm that all authors fulfill the criteria for authorship as given by the Vancouver Recommendations. All authors have read and approved the final version of this manuscript.

Ethics approval and consent to participate
All studies were approved by the local Ethics Committee (Region III, University of Bergen, Norway) and samples collected after written informed consent. Study registrations: ClinicalTrials.gov no. NCT00175812; EudraCT no. 2004–001663-22, ClinicalTrials.gov no. NCT00995332 and EudraCT no. 2007–2007–001995–36.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway. 2Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway. 3Section for Hematology, Institute of Clinical Science, University of Bergen, Bergen, Norway.

Received: 18 July 2016 Accepted: 28 August 2017
Published online: 06 September 2017

References
1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New Eng J Med. 2015;373(12):1136–52.
2. Latağlata R, Bongarzone V, Camosino I, Mengarelli A, Breccia M, Borza PA, D’Andrea M, D’Elia GM, Mecarocci S, Morano SG, et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol. 2006;17(2):281–5.
3. Pollyea DA, Kohut HE, Medeiros BC. Acute myeloid leukemia in the elderly: a review. Br J Haematol. 2011;152(6):524–42.
4. Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–74.
5. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319–27.
6. Skovlund J, Jorgensen KM, Hadziargirovic K, Hovland R, Jonassen I, Bruserud O, Gjertsen BT. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer J. 2011;1:e4.
7. Fredly H, Reikvam H, Gjertsen BT, Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol. 2012;87(4):368–76.
8. Fredly H, Stapnes Bjomsen C, Gjertsen BT, Bruserud O. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukemia—a report of five cases. Hematology. 2010;15(5):338–43.
9. Ryningen A, Stapnes C, Lassalle P, Corbacho M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res. 2009;33(6):779–87.
10. Lubbert M, Kuendingen A. Combining DNA methyltransferase and histone deacetylation inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges. Cancer. 2015;121(4):498–501.
11. Corsetti MT, Salvi F, Perticone S, Balardi A, De Paoli L, Gatto S, Petrasanta D, Pini M, Primon V, Zalilo F, et al. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res. 2011;35(8):991–5.
12. Stapnes C, Gjertsen BT, Reikvam H, Bruserud O. Targeted therapy in acute myeloid leukemia current status and future directions. Expert Opin Investig Drugs. 2009;18(4):433–55.
13. Fredly H, Ensvaer E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenet. 2013;5(1):13.
14. Fredly H, Gjertsen BT, Bruserud O. Histone deacetylation inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenet. 2013;5(1):12.
15. Siddikuzzaman, Guruvayoorappan C, Berlin Grace VM. All trans retinoic acid and cancer. Immunopharmacol Immunotoxicol. 2011;33(2):241–9.
16. Wang ZY, Chen Z. Acute promyelocytic leukemia from highly fatal to highly curable. Blood. 2008;111(9):2505–15.
17. Fredly H, Ensvaer E, Stapnes C, Gjertsen BT, Bruserud Ø. The combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low-Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials. Curr Cancer Ther Rev. 2009;5(4):243–55.
18. Omberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood. 2002;99(6):2199–206.
19. Johnson DE, Redner RL. An ATRAtractive future for differentiation therapy in AML. Blood Rev. 2015;29(4):263–8.
20. Stapnes C, Ryningen A, Hatfield K, Oyan AM, Eide GE, Corbacho M, Kalland KH, Gjertsen BT, Bruserud O. Functional characteristics and gene expression profiles of primary acute myeloid leukemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol. 2007;31(6):1529–38.
21. Trus MR, Yang L, Szarez S, Bordeleau L, Jurisica I, Minden MD. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myelogenous leukemia cells. Leukemia. 2005;19(7):1161–8.
22. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampffmann M, Hoezler D, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005;104(12):2717–25.
23. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Wollman CL, Estey EH, Schiffer CA, Dohner H, Tallman MS, Lister TA, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–9.
24. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, et al. Report of an
international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(2):1671–4.

25. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):1419–25.

26. Bruderud O, Holvand R, Wergeland L, Huang TS, Gjertsen BT. Fli 3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt 3 ligand effects in AML cell populations with and without genetic Flt 3 abnormalities. Haematologica. 2003;88(4):16–28.

27. Robinson JP, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.

28. Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, Forestier E, Jahnskaijen K, Jonsson OG, Zeller B, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905–13.

29. Stavrum AK, Petersen K, Jonassen I, Dysvik B. Analysis of gene-expression data using J-Express. Curr Protoc Bioinforma. 2008, Chapter 7:Unit 7.3; doi:10.1002/047125093X.b7032s21.

30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays data using J-Express. Curr Protoc Bioinforma. 2008, Chapter 7:Unit 7.3; doi:10.1002/047125093X.b7032s21.

31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(4):15545–50.

32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(4):15545–50.

33. Network CGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Eng J Med. 2013;368(21):2059–74.

34. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Herr W, Huber C, Malcovati L, et al. Genomic landscape of myelodysplasia. Blood. 2016;127(4):1286–96.

35. Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia-Manero G, Albitar M, Gaynon P, Oski R, et al. A 17-gene stemness score for rapid determination of risk in acute leukemia. Nature. 2016;540(7633):433–7.

36. Steinmetz B, Hackl H, Slabakov A, Schwarzinger I, Smejova M, Spittler A, Wieser R. New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease. Cell Cycle. 2012;11(21):3915.

37. Wieser R. New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease. Cell Cycle. 2012;11(21):3915.

38. Verhagen HIMP, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, Ossenkoppele GJ, Smit L. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood. 2016;127(4):458–63.

39. Kronenwett R, Butterwick U, Stein DL, Klishewski S, Neumann F, Bork S, Blanco ED, Roes N, Graf T, Bors B, et al. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene. 2005;24(54):8513–24.

40. Rommer A, Steinmetz B, Herbst F, Hackl H, Hefter P, Helios D, Filippits M, Steinleitner K, Hemmati S, Herzberg J, et al. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. PLoS One. 2013(8):e56308.

41. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzker MH, Poeppl A, Ling V, Beyene J, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086–93.

42. Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Pappas C, Gupta V, Schimmer AD, et al. A 17-gene stemness score for rapid determination of risk in acute leukemia. Nature. 2016;540(7633):433–7.

43. Steinmetz B, Hackl H, Slabakov A, Schwarzinger I, Smejova M, Spittler A, Albitar M, Gaynon P, Oski R, et al. Genomic landscape of myelodysplastic syndromes. Blood. 2000;96(12):3678.

44. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzker MH, Poeppl A, Ling V, Beyene J, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086–93.

45. Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Pappas C, Gupta V, Schimmer AD, et al. A 17-gene stemness score for rapid determination of risk in acute leukemia. Nature. 2016;540(7633):433–7.

46. Steinmetz B, Hackl H, Slabakov A, Schwarzinger I, Smejova M, Spittler A, Albitar M, Shehata M,Soucek K, Wieser R. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid. Cell Cycle. 2014;13(18):2951–43.

47. Rommer A, Steinmetz B, Herbst F, Hackl H, Hefter P, Helios D, Filippits M, Steinleitner K, Hemmati S, Herzberg J, et al. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. PLoS One. 2013(8):e56308.

48. Wieser R. New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease. Cell Cycle. 2012;11(21):3915.

49. Verhagen HIMP, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, Ossenkoppele GJ, Smit L. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood. 2016;127(4):458–63.

50. Kronenwett R, Butterwick U, Steidl U, Klishewski S, Neumann F, Bork S, Blanco ED, Roes N, Graf T, Bors B, et al. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene. 2005;24(54):8513–24.